Not recruiting
HER2 negative breast cancer
Not recruitingStudy of Milademetan and Fulvestrant for Patients with Advanced or Metastatic Breast Cancer with GATA3 Mutation, ER-Positive, HER2-Negative
Registered drugNo placebo
Study of Milademetan and Fulvestrant for Patients with Advanced or Metastatic Breast Cancer with GATA3 Mutation, ER-Positive, HER2-Negative
Registered drugNo placebo
- Disease:HER2 negative breast cancer
- Substances:FulvestrantMilademetan
Countries:
France
France- Participants:18–64 years · 65+ years
- Substances:Fulvestrant